Dietel M, Arps H, Bals U, Niendorf A, Henke P, Garbrecht M, Platz D, Weh H J, Thoma G, Klapdor R
Institute für Pathologie, Universität Hamburg sowie Krankenhaus München-Neuperlach.
Dtsch Med Wochenschr. 1989 Oct 27;114(43):1645-52. doi: 10.1055/s-2008-1066809.
An in-vitro test was developed for predicting the efficacy of anti-tumour chemotherapy. Cell cultures were grown from freshly removed tumours and it was then demonstrated by DNA cytophotometry and immuno-cyto-chemistry whether the growing tumour cells corresponded to those of the original tumour cells. Several cytostatic agents were then tested for their efficacy of inhibiting growth at clinically customary dosage. Growing cell cultures were established in 306 of 413 submitted tumours (74%). They responded quite differently to the various drugs that were tried. The clinical course in 94 cases was observed for minimally four and a mean of eight months to obtain an in-vitro to in-vivo correlation of response, with 178 individual correlations. A discrepancy was recorded in 16% of cases, a false-positive in-vitro sensitivity result was 3.6 times more frequently associated with an in vivo resistance than the reverse. Concordance between test results and clinical tumour response occurred in 84%. The monolayer proliferation assay correctly indicated resistance in 93.8%, sensitivity in 72.8%.
已开发出一种体外试验来预测抗肿瘤化疗的疗效。从新切除的肿瘤中培养细胞,然后通过DNA细胞光度法和免疫细胞化学证明生长的肿瘤细胞是否与原始肿瘤细胞一致。然后测试了几种细胞抑制剂在临床常用剂量下抑制生长的疗效。在提交的413个肿瘤中的306个(74%)中建立了生长细胞培养物。它们对所试验的各种药物反应差异很大。观察了94例患者至少4个月、平均8个月的临床病程,以获得体外与体内反应的相关性,共有178个个体相关性。16%的病例记录有差异,体外敏感性结果假阳性与体内耐药性相关的频率是相反情况的3.6倍。试验结果与临床肿瘤反应的一致性为84%。单层增殖试验正确指示耐药性的比例为93.8%,敏感性的比例为72.8%。